Scientists from Fu Wai Hospital of the Chinese Academy of Medical Sciences and Shenzhen Bay Laboratory have divulged cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) inhibitors. They are reported to be useful for the treatment of autoimmune diseases, cancer, neurological disorder, diabetes, inflammatory bowel disease, pulmonary fibrosis, psoriasis and arthritis, among others.
In developed countries, up to 20% of the population suffers from pollen allergies to birch and related trees. Mabylon AG has developed an anti-tree pollen antibody therapeutic, MY-010, that targets several inducers of spring hay fever, such as birch, alder and hazel, among others.
In an article published in Cell Host & Microbe on March 3, 2026, researchers at McMaster University in Canada and at the Hospital Universitario de La Princesa in Spain have shed some light on the impact of microbiota on peanut-driven allergy and anaphylaxis.
Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.
Gliadin is the major allergen of wheat-dependent exercise-induced anaphylaxis (WDEIA). YH-35324 (lesigercept, GI-301) is a long-acting IgEtrap-Fc fusion protein that targets FcεR1α that could serve as a therapeutic approach in WDEIA. It is under development by Yuhan Corp. in early clinical trials as an allergy treatment.
IgE is known to drive allergic disease, and omalizumab is the only approved anti-IgE antibody to date that has shown suboptimal IgE affinity and limited use in scenarios with high IgE levels.
Belgian pharma giant UCB SA is putting skin in the bispecific T-cell engager (TCE) game, announcing a potential $1.1 billion deal to license Antengene Corp.’s ATG-201. ATG-201 is a CD19/CD3 bispecific TCE antibody aimed at autoimmune disorders, though specific indications were not disclosed.
UCB SA and Antengene Corp. Ltd. have entered into a license agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201.
GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology.
Quell Therapeutics Ltd. has delivered the first clinical data indicating its chimeric antigen receptor (CAR) T regulatory cell therapy, QEL-001, can enable liver transplant patients to be weaned off long-term immunosuppression.
RSS
